Matteo Borgini

Matteo Borgini

Auto-generated profile, based on publicly available information

Matteo Borgini

Department of Chemistry and Biochemistry

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2019 in Molecules
Verified
Journal Article
Open access
PDF file
ABAnnalaura BRAI
Annalaura BRAI
SRStefania Ronzini
Stefania Ronzini
VRValentina Riva
Valentina Riva
LBLorenzo Botta
Lorenzo Botta
CZclaudio zamperini
claudio zamperini
MBMaurizio Botta
Maurizio Botta
The human ATPase/RNA helicase X-linked DEAD-box polypeptide 3 (DDX3X) emerged as a novel therapeutic target in the fight against both infectious diseases and cancer. Herein, a new family of DDX3X inhibitors was designed, synthesized, and tested for its inhibitory action on the ATPase activity of the enzyme. The potential use of the most promising derivatives it has been investigated by evaluating their anti-HIV-1 effects, revealing inhibitory activities in the low micromolar range. A preliminary ADME analysis demonstrated high metabolic stability and good aqueous solubility. The promising biological profile, together with the suitable in vitro pharmacokinetic properties, make these novel compounds a very good starting point for further development.

14 January 2021 in RSC Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MBMatteo Borgini
Matteo Borgini
PMPravat Mondal
Pravat Mondal
RLRuiting Liu
Ruiting Liu
PWPeter Wipf
Peter Wipf
The rising interest in Kv7 modulators originates from their ability to evoke fundamental electrophysiological perturbations in a tissue-specific manner. A large number of therapeutic applications are, in part, based on the clinical experience with two broad-spectrum Kv7 agonists, flupirtine and retigabine. Since precise molecular structures of human Kv7 channel subtypes in closed and open states have only very recently started to emerge, computational studies have traditionally been used to analyze binding modes and direct the development of more potent and selective Kv7 modulators with improved safety profiles. Herein, the synthetic and medicinal chemistry of small molecule modulators and the representative biological properties are summarized. Furthermore, new therapeutic applications supported by in vitro and in vivo assay data are suggested.

20 May 2024 in Journal of the American Chemical Society
Verified
Journal Article
Open access
MBMatteo Borgini
Matteo Borgini
QHQi-Nan Huang
Qi-Nan Huang
PCPan-Pan Chen
Pan-Pan Chen
SGSteven J. Geib
Steven J. Geib
KHKendall N Houk
Kendall N Houk
PWPeter Wipf
Peter Wipf
Bicyclo[1.1.0]butane-containing compounds feature a unique chemical reactivity, trigger "strain-release" reaction cascades, and provide novel scaffolds with considerable utility in the drug discovery field. We report the synthesis of new bicyclo[1.1.0]butane-linked heterocycles by a nucleophilic addition of bicyclo[1.1.0]butyl anions to 8-isocyanatoquinoline, or, alternatively, iminium cations derived from quinolines and pyridines. The resulting bicyclo[1.1.0]butanes are converted with high regioselectivity to unprecedented bridged heterocycles in a rhodium(I)-catalyzed annulative rearrangement. The addition/rearrangement process tolerates a surprisingly large range of functional groups. Subsequent chemo- and stereoselective synthetic transformations of urea, alkene, cyclopropane, and aniline moieties of the 1-methylene-5-azacyclopropa[cd]indene scaffolds provide several additional new heterocyclic building blocks. X-ray structure-validated quantum mechanical DFT calculations of the reaction pathway indicate the intermediacy of rhodium carbenoid and metallocyclobutane species.

1 March 2020 in International Journal of Antimicrobial Agents
Verified
Journal Article
Closed access
FOFrancesco Orofino
Francesco Orofino
GTGiuseppina I. Truglio
Giuseppina I. Truglio
DFDiego Fiorucci
Diego Fiorucci
IDIlaria D'Agostino
Ilaria D'Agostino
MBMatteo Borgini
Matteo Borgini
MBMaurizio Botta
Maurizio Botta

7 February 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
MBMatteo Borgini
Matteo Borgini
CZclaudio zamperini
claudio zamperini
Federica PoggialiniFederica Poggialini
Federica Poggialini
LFLuca Ferrante
Luca Ferrante
VSVincenzo Summa
Vincenzo Summa
RFRomano Di Fabio
Romano Di Fabio
The marine natural product Largazole is the most potent Class I HDAC inhibitor identified to date. Since its discovery, many research groups have been attracted by the structural complexity and the peculiar anticancer activity, due to its capability to discriminate between tumor cells and normal cells. Herein, we discuss the synthesis and the in vitro biological profile of hybrid analogues of Largazole, as dual HDAC inhibitor and nitric oxide (NO) donors, potentially useful as anticancer agents. In particular, the metabolic stability of the modified thioester moiety of Largazole, bearing the NO-donor function/s, the in vitro release of NO, and the antiproliferative activity in tumor cell lines are presented.

7 November 2023 in Organic & Biomolecular Chemistry
Verified
Journal Article
Open access
PDF file
MBMatteo Borgini
Matteo Borgini
ŁWŁukasz Wieteska
Łukasz Wieteska
CHCynthia S. Hinck
Cynthia S. Hinck
TKTroy Krzysiak
Troy Krzysiak
AHAndrew Hinck
Andrew Hinck
PWPeter Wipf
Peter Wipf
13C Methyl-labeled amino acids are prepared by a Pd-catalyzed C(sp3)–H functionalization and can be incorporated into human receptor extracellular domains with multiple disulfides using mammalian suspension-cultured HEK293 cells.